ORASURE TECHNOLOGIES INC (OSUR): Results of Operations and Financial Condition
ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 osur-pressreleaseq22026.htm EX-99.1 Document EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nas
How this was made
The 30-second read
Why it matters
Traders can update models using the disclosed Q2 financials and the explicit Q3 revenue range, while also factoring regulatory milestones that may drive future test adoption and platform utilization.
Market read
The combination of Q2 financial improvement, explicit Q3 guidance, and two FDA milestones creates a tradable catalyst set for OSUR around the filing and subsequent earnings positioning.
What to watch
The 8-K notes a $22.6M reduction in contingent consideration liability tied to FDA feedback for the Sherlock CT/NG test submission plan, which may not be purely operational and could affect comparability versus prior periods.
Background
This is an SEC Form 8-K (Item 2.02) with an attached press release covering OraSure’s Q2 2026 financial results, recent FDA regulatory updates, and Q3 2026 revenue guidance.
Ticker impact
OraSure reports Q2 2026 results and guides Q3 2026 total revenues to $29.5M-$32.5M, plus FDA clearances for Colli-Pee Dx and OraQuick Ebola 2.0.
Likely positive bias for near-term trading as guidance and FDA clearances support a return-to-growth narrative, though the magnitude depends on how the market compares the Q3 range to consensus.
The article discloses specific Q2 revenue, margin, EPS, cash balance, share repurchases, and a concrete Q3 revenue range, plus FDA clearance/EUA events that can affect product adoption and revenue trajectory.
Market effects
Supports sentiment for point-of-need and home diagnostics, highlighting continued FDA activity and decentralization of testing.
Limited, primarily affects US small-cap biotech/diagnostics sentiment rather than broad regional flows.
Moderate, as Ebola test EUA and STI at-home collection kit clearance can influence global preparedness and diagnostics demand narratives.
Counterpoint
Despite improved Q2 profitability, core revenues are described as largely flat year-over-year and non-GAAP operating loss remains, so the guidance may not fully offset underlying demand softness.
Key entities
- companyOraSure Technologies, Inc.
Nasdaq-listed diagnostics company reporting Q2 2026 results, FDA clearance/EUA updates, and Q3 2026 revenue guidance.
- regulatorFDA
Cleared OraSure’s Colli-Pee Dx urine collection kit and issued EUA for OraQuick Ebola 2.0 Rapid Antigen Test.
- partnerRoche
OraSure’s Colli-Pee Dx kit is intended for testing on Roche’s cobas molecular diagnostics platform.
